The study reported a 62% reduction in breast cancer with prophylactic tamoxifen in healthy BRCA2-mutation carriers, but there was no reduction in breast cancer incidence among women with an inherited BRCA1 mutation. The gene discussed is BRCA2; the disease is breast carcinoma.